NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM1619464 Query DataSets for GSM1619464
Status Public on Oct 06, 2015
Title sample_87_01-PD-016 [expression]
Sample type RNA
 
Source name Breast cancer, CHER-LOB Arm C, pre-treated
Organism Homo sapiens
Characteristics disease state: HER2-positive breast cancer
tissue: breast cancer
cher-lob arm: C
arm description: chemotherapy+trastuzumab+lapatinib
pcr (1=yes): 0
Treatment protocol CHER-LOB is a phase II, randomized, multicenter, trial in which 121 patients with primary HER2-positive breast cancer were randomized to receive preoperative chemotherapy with weekly paclitaxel times 12 followed by 4 courses of 3-weekly FEC (fluorouracil, epirubicin and cyclophosphamide) plus either trastuzumab (Arm A), lapatinib (Arm B) or the combination of trastuzumab and lapatinib (Arm C). The trial design, eligibility criteria, statistical analysis, and clinical results including response, surgery outcomes and treatment safety are described in details elsewhere.
Growth protocol NA
Extracted molecule total RNA
Extraction protocol Qiagen RNeasy (manufacturer's protocol).
Label Biotin
Label protocol Affymetrix GeneChipĀ® 3' IVT Express Kit (manufacturer's protocol).
 
Hybridization protocol Affymetrix Human Genome U133 Plus 2.0 array (manufacturer's protocol).
Scan protocol Affymetrix GeneChip Scanner 3000 7G (manufacturer's protocol).
Data processing Partek GS.
 
Submission date Feb 25, 2015
Last update date Jun 06, 2022
Contact name Enrico Tagliafico
E-mail(s) enrico.tagliafico@unimore.it
Organization name University of Modena and Reggio Emilia
Department Center for Genome Research
Street address Via Campi 287
City Modena
State/province MO
ZIP/Postal code 41126
Country Italy
 
Platform ID GPL570
Series (2)
GSE66305 Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [expression]
GSE66399 Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer
Relations
Reanalyzed by GSE205568

Data table header descriptions
ID_REF
VALUE RMA signal

Data table
ID_REF VALUE
1007_s_at 10.4886
1053_at 8.51363
117_at 6.83154
121_at 7.39513
1255_g_at 3.13098
1294_at 7.3209
1316_at 6.36563
1320_at 4.27534
1405_i_at 9.57975
1431_at 3.38714
1438_at 5.00096
1487_at 7.42874
1494_f_at 5.4291
1552256_a_at 7.68373
1552257_a_at 7.95748
1552258_at 4.55509
1552261_at 3.46953
1552263_at 6.88334
1552264_a_at 7.04058
1552266_at 2.73476

Total number of rows: 54675

Table truncated, full table size 998 Kbytes.




Supplementary file Size Download File type/resource
GSM1619464_87_01-PD-016_HG-U133_Plus_2_.CEL.gz 4.7 Mb (ftp)(http) CEL
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap